October 2019 Volume 15, Issue 10
Volume 15, Issue 10 | October 2019
October 2019
In this Issue
Feature
Focus Feature on CRISPR Gene Editing: What’s new with CRISPR?
A roundup of recent news and breakthroughs with the gene-editing technologyAMP 2019 Show Preview: Marking a quarter-century of molecular pathology
Association for Molecular Pathology brings its annual meeting and expo to BaltimoreDiscovery
Going GENTRL
Insilico Medicine has validated its new GENTRL AI systemGetting to grips with chemoresistance
Scientists develop drug-resistant cell line for lymphoma to better model disease development and drug reactionsA path to prevent addiction?
Scripps Research finds an anti-opioid pathwayAI answers
Atomwise collaborates for drug developmentDiagnostics
AI-based blood testing
Diagnostics detect cancer in dense breastsT2 keeps trucking along
Company’s direct-from-blood diagnostic tests post strong data, supporting multiple distribution agreementsA focus on FFPE
Pressure BioSciences’ PCT platform lauded for its ability to process cancer biopsy samplesWhat’s the hubbub?
NUS, Agilent and NUH launch new translational R&D hub to boost clinical diagnosticsScientists create a faster DNA testing method
New ‘Vilnius-made’ method reportedly reduces DNA testing costs by 90 percentResearch & Development
Pinpointing patients
Researchers identify immune biomarker showing which HCC patients would benefit most from sorafenibBrain vs. brain
Brain organoids and brains of premature babies generate similar EEG patternsGut check
French biotech company raises €6.2M for gut microbiome R&DTeaming up on autoimmune disease
Exagen and University of Washington collaborate on lupus and rheumatoid arthritis researchPushing against cancer
Crescendo to collaborate with University of Oxford and University of SurreySpecial Reports
Special Report on Cell Biology: Making bioprogress
Expanding bioprocess analytics to ensure qualityEditor's Focus
Editor’s Focus: An embarrassment of riches
From a Focus Feature to Q&As, there's no shortage of bonus pieces in our October issue; no matter which indications interest you most, there's something for everyoneContract Services
Making moves
Sygnature Discovery moves U.S. base to Kendall SquareBusiness & Government Policy
New campaign focuses on fighting superbugs
Working to Fight AMR aims to spur development of new antibioticsOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsNot passing the finish line
Many pre-approved prescription drugs have not completed FDA approval processCannabidiol vs. epilepsy
NICE to work with GW Pharma on appraisals of cannabidiolClinical Trials
Battling Batten disease
Amicus gene therapy brings in positive interim resultsSafety and statistical significance
Patients respond well to Aclaris’ ATI-501 in alopecia areata trialAn influx of focus on wet AMD
A trio of companies report trial progression or positive data for AMD-targeted therapeuticsPreclinical
Positive results for radiation prophylaxis
Pluristem and the Department of Defense present positive PLX-R18 dataHealthy data for Cytokinetics' HCM candidate
CK-274, which addresses hypercontractility in hypertrophic cardiomyopathy, reduces contractility in preclinical modelsRodents to the rescue
Taconic and ContraVir report positive preclinical tests for treating NASHCommentary
Optimized dosing: We can do better, but when?
While we are increasingly able to make better drug choices for subpopulations thanks to companion diagnostics and more, actually optimizing dosing for an individual is an aspirational goal right now
